Climb Bio, Inc.
PublicClimb Bio, Inc. is now publicly traded
The data on this page reflects Climb Bio, Inc.'s private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Private Placement
Apr 29, 2026
Total Funding Raised
$185.08M
Company Overview
Climb Bio, Inc. operates in Biotech and is based in Massachusetts. It has raised $185.08M.
Climb Bio, Inc. is a clinical-stage biotechnology company that develops monoclonal antibody therapeutics for immune-mediated and autoantibody-driven diseases.
Sector
Biotech
AI Layer
Non-AI
Climb Bio, Inc. Comparables
Compare Climb Bio, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Biogen | 75% | |
| Cerium Pharmaceuticals, Inc. | 54% |
For institutional investors. Book with your work email.
Climb Bio, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Apr 29, 2026 | ||||
| Private Placement | May 21, 2021 | ||||
| Private Placement | Oct 16, 2020 | ||||
| Private Placement | Oct 10, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Climb Bio, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Private Placement |
| ADAR1 Capital Management | Private Placement |
| RA Capital Management | Private Placement |
| Ally Bridge Group | Private Placement |
| Driehaus Capital Management | Private Placement |
| Adage Capital Management | Private Placement |
| Cormorant Asset Management | Private Placement |
For institutional investors. Book with your work email.
Climb Bio, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.